232 related articles for article (PubMed ID: 33719089)
1. Preferentially expressed antigen in melanoma expression in nonmelanoma skin cancers and melanocytes in surrounding skin.
Elsensohn A; Hanson J; Ferringer T
J Cutan Pathol; 2021 Sep; 48(9):1150-1155. PubMed ID: 33719089
[TBL] [Abstract][Full Text] [Related]
2. PRAME immunostain expression in sebaceous lesions, cutaneous carcinomas and adnexal structures.
Ng JKM; Choi PCL; Chow C; Li JJX; Chan AWS; Cheung CMT; Ip ECC; Ng HK; To KF
Pathology; 2022 Oct; 54(6):721-728. PubMed ID: 35644638
[TBL] [Abstract][Full Text] [Related]
3. Preferentially Expressed Antigen in Melanoma Immunostaining in a Series of Melanocytic Neoplasms.
Googe PB; Flanigan KL; Miedema JR
Am J Dermatopathol; 2021 Nov; 43(11):794-800. PubMed ID: 33989214
[TBL] [Abstract][Full Text] [Related]
4. The utility of PRAME staining in identifying malignant transformation of melanocytic nevi.
Lohman ME; Steen AJ; Grekin RC; North JP
J Cutan Pathol; 2021 Jul; 48(7):856-862. PubMed ID: 33433032
[TBL] [Abstract][Full Text] [Related]
5. The utility of PRAME immunohistochemistry in the evaluation of challenging melanocytic tumors.
Alomari AK; Tharp AW; Umphress B; Kowal RP
J Cutan Pathol; 2021 Sep; 48(9):1115-1123. PubMed ID: 33660310
[TBL] [Abstract][Full Text] [Related]
6. PRAME expression in melanocytic proliferations with intermediate histopathologic or spitzoid features.
Raghavan SS; Wang JY; Kwok S; Rieger KE; Novoa RA; Brown RA
J Cutan Pathol; 2020 Dec; 47(12):1123-1131. PubMed ID: 32700786
[TBL] [Abstract][Full Text] [Related]
7. PRAME expression in spindle cell melanoma, malignant peripheral nerve sheath tumour, and other cutaneous sarcomatoid neoplasms: a comparative analysis.
Hrycaj SM; Szczepanski JM; Zhao L; Siddiqui J; Thomas DG; Lucas DR; Patel RM; Harms PW; Bresler SC; Chan MP
Histopathology; 2022 Dec; 81(6):818-825. PubMed ID: 36102613
[TBL] [Abstract][Full Text] [Related]
8. PRAME expression in melanocytic lesions of the nail.
Parra O; Linos K; Li Z; Yan S
J Cutan Pathol; 2022 Jul; 49(7):610-617. PubMed ID: 35294053
[TBL] [Abstract][Full Text] [Related]
9. UV-Induced Molecular Signaling Differences in Melanoma and Non-melanoma Skin Cancer.
Liu-Smith F; Jia J; Zheng Y
Adv Exp Med Biol; 2017; 996():27-40. PubMed ID: 29124688
[TBL] [Abstract][Full Text] [Related]
10. PRAME Updated: Diagnostic, Prognostic, and Therapeutic Role in Skin Cancer.
Cassalia F; Danese A; Tudurachi I; Federico S; Zambello A; Guidotti A; Franceschin L; Bolzon A; Naldi L; Belloni Fortina A
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338862
[TBL] [Abstract][Full Text] [Related]
11. PReferentially expressed antigen in MElanoma (PRAME) expression in BRCA1-associated protein (BAP1)-inactivated melanocytic tumors and deep penetrating nevi: A pilot study.
Lopez DR; Forcucci JA; O'Connor H; Maize JC
J Cutan Pathol; 2021 Apr; 48(4):597-600. PubMed ID: 33094849
[No Abstract] [Full Text] [Related]
12. Aberrant expression of HMB45 and negative PRAME expression in halo nevi.
Ruby KN; Li Z; Yan S
J Cutan Pathol; 2021 Apr; 48(4):519-525. PubMed ID: 33184871
[TBL] [Abstract][Full Text] [Related]
13. Pitfalls of PRAME Immunohistochemistry in a Large Series of Melanocytic and Nonmelanocytic Lesions With Literature Review.
Turner N; Ko CJ; McNiff JM; Galan A
Am J Dermatopathol; 2024 Jan; 46(1):21-30. PubMed ID: 37982498
[TBL] [Abstract][Full Text] [Related]
14. Preferentially Expressed Nuclear Antigen in Melanoma Expression in Melanocytic Activation (Melanotic Macule) of the Nail Unit. A Potential Diagnostic Pitfall? A Study of 3 Cases.
Perrin C
Am J Dermatopathol; 2022 Jul; 44(7):499-502. PubMed ID: 35220324
[TBL] [Abstract][Full Text] [Related]
15. PRAME Expression in Melanocytic Tumors.
Lezcano C; Jungbluth AA; Nehal KS; Hollmann TJ; Busam KJ
Am J Surg Pathol; 2018 Nov; 42(11):1456-1465. PubMed ID: 30045064
[TBL] [Abstract][Full Text] [Related]
16. Ber EP4 and epithelial membrane antigen aid distinction of basal cell, squamous cell and basosquamous carcinomas of the skin.
Beer TW; Shepherd P; Theaker JM
Histopathology; 2000 Sep; 37(3):218-23. PubMed ID: 10971697
[TBL] [Abstract][Full Text] [Related]
17. Melanocytes express 3G5 surface antigen.
Fiedler E; Nayak RC; Marsch WCh; Helmbold P
Am J Dermatopathol; 2004 Jun; 26(3):200-4. PubMed ID: 15166506
[TBL] [Abstract][Full Text] [Related]
18. PRAME immunohistochemistry can distinguish melanocytic pseudonests of lichenoid reactions from melanoma in situ.
Roy SF; Panse G; McNiff JM
J Cutan Pathol; 2023 May; 50(5):450-454. PubMed ID: 36789669
[TBL] [Abstract][Full Text] [Related]
19. Glioma-Associated Oncogene-1 Expression in Basal Cell Carcinoma and Its Histologic Mimics.
Gradecki SE; Eid MV; Pramoonjago P; Wick MR
Am J Dermatopathol; 2021 Sep; 43(9):637-641. PubMed ID: 33264133
[TBL] [Abstract][Full Text] [Related]
20. p63 is a useful marker for cutaneous spindle cell squamous cell carcinoma.
Dotto JE; Glusac EJ
J Cutan Pathol; 2006 Jun; 33(6):413-7. PubMed ID: 16776716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
